,i #aaith ,,congress #b;d ,session ,h4 ,r4 #iafi ,,in ,,the ,,house ,,of ,,representatives ,june #d1 #bjbf,ms4 ,wasserman ,schultz 7for herself1 ,mrs4 ,miller of ,west ,virginia1 ,mr4 ,cleaver1 and ,mr4 ,bacon7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to support polycystic kidney disease research1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,,pkd ,cures ,act4 #b4 ,findings ,congress finds the following3 7#a7 ,polycystic kidney disease 7in this section referred to as ,,pkd7 is one of the most common life-threatening genetic diseases1 affecting approximately #ejj1jjj ,americans and millions worldwide4 7#b7 ,,pkd leads to end-stage renal disease1 or kidney failure1 in the majority of affected individuals1 necessitating dialysis and transplantation4 7#c7 ,more than #e percent of patients enrolled in the ,medicare ,end-,stage ,renal ,disease program have kidney failure caused by cystic kidney disease1 primarily ,,pkd4 7#d7 ,end-stage renal disease and kidney failure attributable to cystic kidney diseases1 like ,,pkd1 cost ,medicare an estimated #c1jjj1jjj1jjj annually4 #c4 ,expansion of ,,nih research on polycystic kidney disease ,subpart #c of part ,c of title ,,iv of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bhe;c et seq47 is amended by adding at the end the following3 #dcd;,b4 ,expansion of ,,nih research on polycystic kidney disease 7a7 ,research focus ,the ,director of the ,institute shall expand and intensify research activities regarding polycystic kidney disease 7in this section referred to as ,,pkd71 including-- 7#a7 basic research to understand the genetic and molecular mechanisms of ,,pkd2 7#b7 translational research to identify biomarkers and potential therapeutic targets2 and 7#c7 clinical research to evaluate the safety and efficacy of new and existing treatments4 7b7 ,collaboration ,in implementing the requirements of subsection 7a71 the ,director of the ,institute shall-- 7#a7 collaborate with other ,federal agencies1 academic institutions1 and private sector stakeholders to accelerate the development of treatments and cures2 and 7#b7 support training programs to cultivate a workforce of researchers and clinicians specializing in ,,pkd4 7c7 ,priority ,in implementing the requirements of subsection 7a71 the ,director of the ,institute shall prioritize research proposals that demonstrate a clear potential to advance understanding and treatment of ,,pkd4 #dcd;,c4 ,development of comprehensive ,,pkd roadmap 7a7 ,in general ,the ,director of ,,nih shall establish a working group to develop a comprehensive roadmap for polycystic kidney disease 7in this section referred to as ,,pkd7 research and innovation4 7b7 ,membership ,the ,director of ,,nih shall appoint the members of the working group1 who shall be-- 7#a7 experts in nephrology1 human genetics1 or molecular and cellular biology with expertise in the mechanistic pathways of ,,pkd2 7#b7 representatives of ,,pkd patient advocacy organizations2 or 7#c7 such other stakeholders as the ,director determines appropriate4 7c7 ,responsibilities ,in developing the comprehensive roadmap referred to in subsection 7a71 the working group shall-- 7#a7 identify research gaps and priorities2 7#b7 recommend strategies to enhance collaboration between the public and private sectors2 7#c7 propose timelines and benchmarks for achieving key milestones in ,,pkd innovation2 and 7#d7 develop a plan for integrating new technologies1 such as artificial intelligence and precision medicine1 into ,,pkd research and care4 7d7 ,report ,not later than #bd months after the date of enactment of this section1 the working group shall submit to ,congress a report detailing the findings and recommendations of the working group1 including the comprehensive roadmap referred to in subsection 7a74 4